acitretin has been researched along with Melanoma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II | 1 |
| Cranmer, L; Curiel-Lewandrowski, C; Erickson, CP; LaPresto, L; Morrison, L | 1 |
| Anforth, R; Blumetti, TC; Clements, A; Fernandez-Peñas, P; Kefford, R; Long, GV | 1 |
| Chon, SY; Geddes, ER; Sambrano, BL | 1 |
| Fenchel, K; Sachse, MM; Wagner, G | 1 |
| Assouly, P; Consoli, SG; Mahé, E; Martin, L; Penso-Assathiany, D | 1 |
| Plaza, JA; Ravikumar, S; Schieke, SM; Troy, JL; Yu, J | 1 |
| Arcese, A; Camplone, G; Carlesimo, M; Di Russo, PP; Gamba, A; La Pietra, M; Mari, E; Orsini, D | 1 |
| Anforth, R; Blumetti, TC; Fernandez-Penas, P; Mohd Affandi, A | 1 |
| Lei, XB; Qiu, S; Ran, LW; Tan, SS; Wang, WJ; Zeng, WH | 1 |
10 other study(ies) available for acitretin and Melanoma
| Article | Year |
|---|---|
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Topics: Acitretin; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dermatitis; Drug Eruptions; Drug Therapy, Combination; Exportin 1 Protein; Female; Fluocinonide; Glucocorticoids; Humans; Hypertrophy; Immune Checkpoint Inhibitors; Karyopherins; Keratolytic Agents; Lichenoid Eruptions; Melanoma; Programmed Cell Death 1 Receptor; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triamcinolone | 2020 |
A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
Topics: Acitretin; Aged; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Indoles; Injections, Intralesional; Keratoacanthoma; Keratolytic Agents; Male; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.
Topics: Acitretin; Aged; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cohort Studies; Female; Humans; Imidazoles; Indoles; Keratolytic Agents; Keratosis; Male; Melanoma; Middle Aged; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sulfonamides; Vemurafenib | 2013 |
Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Topics: Acitretin; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoprevention; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Keratolytic Agents; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Sulfonamides; Vemurafenib | 2014 |
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
Topics: Acitretin; Adult; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Eyelid Diseases; Female; Humans; Indoles; Keratoacanthoma; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 1; MAP Kinase Signaling System; Melanoma; Neoplasm Staging; Neoplasms, Unknown Primary; Proto-Oncogene Proteins B-raf; Signal Transduction; Sulfonamides; Vemurafenib | 2014 |
[Saying no].
Topics: Acitretin; Adult; Antibodies, Monoclonal; Child; Choice Behavior; Contraindications; Cosmetic Techniques; Erythrokeratodermia Variabilis; Female; Humans; Hyaluronic Acid; Immunosuppressive Agents; Interprofessional Relations; Ipilimumab; Kidney Failure, Chronic; Kidney Transplantation; Melanoma; Physician-Patient Relations; Postoperative Complications; Refusal to Treat; Tattooing | 2014 |
Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
Topics: Acitretin; Aged; Biopsy; Cell Proliferation; Drug Eruptions; Eccrine Glands; Epithelial Cells; Humans; Indoles; Keratolytic Agents; Male; Melanoma; Metaplasia; Skin Neoplasms; Sulfonamides; Treatment Outcome; Vemurafenib | 2015 |
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Melanoma; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib.
Topics: Acitretin; Aged; Carcinoma, Squamous Cell; Humans; Indoles; Keratolytic Agents; Male; Melanoma; Retinoids; Skin Neoplasms; Sulfonamides; Vemurafenib | 2012 |
[Effects of all-trans-retinoic acid, acitretin and tazarotene on apoptosis and Bax/Bcl-2 expressions of human melanoma cells A375 and the significance].
Topics: Acitretin; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Humans; Melanoma; Nicotinic Acids; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Tretinoin; Tumor Cells, Cultured | 2005 |